Covid-19 infection in patients with proven heart disease

Objective: The COVID-19 pandemic remains a hot topic whose results are highly uncertain. This acute respiratory infection is mainly transmitted through respiratory droplets and contact routes. Frail patients such as those with severe heart disease are at higher risk of contracting moderate to severe forms of COVID-19 pneumonia. our goal was to determine the prevalence of COVID-19 in patients with proven heart failure and to give the result of this disease. Design and method: We collected data from the medical records of heart failure patients followed at the Medical and Cardiology Center over the past two years and looked for the onset of COVID-19 disease, risk factors for poor outcomes as well as the final outcome of the disease. Results: Out of 130 medical records, we recorded a total of 66 cases. The mean age of patients was 61.4 ± 17.8 years. The sex ratio was 0.81. LV systolic function was preserved in 47.7% of cases. COVID-19-related pneumonia was detected in 14.9% of cases; The clinical presentation was dominated by respiratory distress associated with moderate oxygen desaturation and fever. Forty-six patients (70.7%) were on renin-angiotensin-aldosterone inhibitors. Poor outcome factors were: BT systolic dysfunction (52.3%), atrial fibrillation (31.3%), pulmonary arterial hypertension (16.4%), impaired renal function (41.8%), impaired liver function (59.7%), and at least 10-fold increase in NT-Pro-BNP values (55.2%). In addition, LVH was observed in 32.8% of cases, complete LBBB in 13.4% of cases, and significant LV dilation in 55.2% of cases. There have been 8 deaths, including 5 related to COVID-19-related pneumonia. Survivors received long-term chest physiotherapy in addition to treatment for heart failure. Conclusions: Acute pneumonia due to COVID-19 can have a negative impact on the prognosis of heart disease. Thus, the factors of poor performance should encourage the isolation and/or treatment of these at-risk populations.